Arrowhead Pharmaceuticals (NASDAQ:ARWR) PT Raised to $46.00 at B. Riley

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target boosted by B. Riley from $32.00 to $46.00 in a research report sent to investors on Monday, BenzingaRatingsTable reports. They currently have a buy rating on the biotechnology company’s stock.

ARWR has been the topic of a number of other reports. ValuEngine downgraded Arrowhead Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Thursday, August 1st. TheStreet upgraded Arrowhead Pharmaceuticals from a d rating to a c+ rating in a research report on Thursday, May 30th. Cantor Fitzgerald downgraded Arrowhead Pharmaceuticals from an overweight rating to a neutral rating and set a $24.00 price objective on the stock. in a research report on Thursday, June 27th. Piper Jaffray Companies upped their price objective on Arrowhead Pharmaceuticals from $33.00 to $50.00 and gave the company an overweight rating in a research report on Tuesday, August 6th. Finally, BidaskClub upgraded Arrowhead Pharmaceuticals from a hold rating to a buy rating in a research report on Friday, July 19th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $33.70.

NASDAQ:ARWR opened at $34.50 on Monday. The company has a market capitalization of $3.20 billion, a P/E ratio of -53.08 and a beta of 1.59. Arrowhead Pharmaceuticals has a 12 month low of $10.41 and a 12 month high of $35.41. The business’s 50-day moving average is $28.98 and its 200 day moving average is $22.59.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Monday, August 5th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.34 by ($0.13). Arrowhead Pharmaceuticals had a net margin of 33.28% and a return on equity of 26.27%. The company had revenue of $42.70 million for the quarter, compared to analysts’ expectations of $59.05 million. Equities research analysts predict that Arrowhead Pharmaceuticals will post 0.73 earnings per share for the current year.

In other news, Director Mauro Ferrari sold 17,756 shares of the stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $27.61, for a total value of $490,243.16. Following the sale, the director now directly owns 1,900 shares in the company, valued at $52,459. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, General Counsel Patrick O’brien sold 30,000 shares of the stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $24.88, for a total value of $746,400.00. Following the completion of the sale, the general counsel now owns 203,000 shares in the company, valued at $5,050,640. The disclosure for this sale can be found here. Corporate insiders own 4.80% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Sound Income Strategies LLC bought a new position in Arrowhead Pharmaceuticals in the second quarter worth approximately $34,000. Acadian Asset Management LLC bought a new position in Arrowhead Pharmaceuticals in the second quarter worth approximately $34,000. Mascoma Wealth Management LLC bought a new position in Arrowhead Pharmaceuticals in the second quarter worth approximately $46,000. First Quadrant L P CA grew its stake in Arrowhead Pharmaceuticals by 831.4% in the first quarter. First Quadrant L P CA now owns 3,353 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 2,993 shares in the last quarter. Finally, Pearl River Capital LLC bought a new position in Arrowhead Pharmaceuticals in the second quarter worth approximately $111,000. 73.52% of the stock is currently owned by institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.

Read More: Technical Analysis of Stocks, How Can It Help

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.